Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: A long-term follow-up study

Journal of the American College of Cardiology

Volumn 43, Issue 12, 2004, Pages 2225-2232

  Sposito, Andrei C ^a   Lemos, Pedro A ^b   Santos, Raul D ^b   Hueb, Whady ^b   Vinagre, Carmen G C ^b   Quintella, Edgard ^b   Carneiro, Otavio ^b   Chapman, M John ^c   Ramires, Jose A F ^a,b   Maranhão, Raul C ^b  

^a FUNDAÇÃO ZERBINI   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

ACAD; ACE; aggravating coronary artery disease; angiotensin converting enzyme; CAD; CE; cholesterol ester; CI; confidence interval; coronary artery disease; delipidation index; DI; FCR; fractional clearance rate; hazard ratio; HDL; high density lipoprotein; HR; LDL

Indexed keywords

CHOLESTEROL ESTER; CHYLOMICRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; ISOTOPE LABELING; LIPID DEGRADATION; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 2942518215     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.065     Document Type: Article

References (26)

1. Eckel R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med. 320:1989;1060-1068
2. Goldberg I.J. Lipoprotein lipase and lipolysis Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 37:1996;693-707
3. Maranhao R.C., Feres M.C., Martins M.T., et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis. 126:1996;15-25
4. Sposito A.C., Maranhao R.C., Vinagre C.G., Santos R.D., Ramires J.A. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis. 154:2001;455-461
5. Wittrup H.H., Tybjaerg-Hansen A., Nordestgaard B.G. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 99:1999;2901-2907
6. Santos R.D., Sposito A.C., Ventura L.I., Cesar L.A., Ramires J.A., Maranhao R.C. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am J Cardiol. 85:2000;1163-1166
7. Marsh J.B., Welty F.K., Lichtenstein A.H., Lamon-Fava S., Schaefer E.J. Apolipoprotein B metabolism in humans Studies with stable isotope-labeled amino acid precursors. Atherosclerosis. 162:2002;227-244
8. Santos R.D., Ventura L.I., Sposito A.C., Schreiber R., Ramires J.A., Maranhao R.C. The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. Cardiovasc Res. 49:2001;456-465
9. Sposito A.C., Santos R.D., Hueb W., et al. LDL concentration is correlated with the removal from the plasma of a chylomicron-like emulsion in subjects with coronary artery disease. Atherosclerosis. 161:2002;447-453
10. Nakandakare E.R., Lottenberg S.A., Oliveira H.C., et al. Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion Studies in normolipidemic and hyperlipidemic subjects. J Lipid Res. 35:1994;143-152
11. Redgrave T.G., Zech L.A. A kinetic model of chylomicron core lipid metabolism in rats The effect of a single meal. J Lipid Res. 28:1987;473-482
12. Sposito A.C., Santos R.D., Amancio R., et al. Statins effects on plasma removal of chylomicrons and remnants in coronary artery disease Study with artificial emulsions. Eur Heart J. 20:1999;175
13. Yang J.Y., Kim T.K., Koo B.S., Park B.H., Park J.W. Change of plasma lipoproteins by heparin-released lipoprotein lipase. Exp Mol Med. 31:1999;60-64
14. Leidig G.A. Jr., Pasternak R.C., Horowitz G., Ginsburg G.S. Effects of heparin and cardiac catheterization on serum lipoprotein and triglyceride levels. Am J Cardiol. 74:1994;47-52
15. Tornvall P., Olivecrona G., Karpe F., Hamsten A., Olivecrona T. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol. 15:1995;1086-1093
16. Redgrave T.G., Maranhao R.C. Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta. 835:1985;104-112
17. Maranhao R.C., Tercyak A.M., Redgrave T.G. Effects of cholesterol content on the metabolism of protein-free emulsion models of lipoproteins. Biochim Biophys Acta. 875:1986;247-255
18. Redgrave T.G., Ly H.L., Quintao E.C., Ramberg C.F., Boston R.C. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man. Biochem J. 290:1993;843-847
19. Karpe F., Hultin M. Endogenous triglyceride-rich lipoproteins accumulate in rat plasma when competing with a chylomicron-like triglyceride emulsion for a common lipolytic pathway. J Lipid Res. 36:1995;1557-1566
20. Bjorkegren J., Packard C.J., Hamsten A., et al. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res. 37:1996;76-86
21. Martins I.J., Mortimer B.C., Miller J., Redgrave T.G. Effects of particle size and number on the plasma clearance of chylomicrons and remnants. J Lipid Res. 37:1996;2696-2705
22. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 105:2002;1162-1169
23. Lundman P., Eriksson M., Schenck-Gustafsson K., Karpe F., Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 96:1997;3266-3268
24. Vogel R.A., Corretti M.C., Plotnick G.D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 79:1997;350-354
25. Hodis H.N., Mack W.J. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J. 19:(Suppl A):1998;A40-A44
26. Karpe F., Taskinen M.R., Nieminen M.S., et al. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis. 157:2001;181-187